Claims:

1. (Currently Amended) A compound according to formula I:



I

wherein X is H, halogen, or CN;

R^1 and R^2 are independently H, C_1-C_6 alkyl, -$(CH_2)_k$-aryl, -$(CH_2)_k$-heteroaryl, wherein said alkyl, -$(CH_2)_k$-aryl or -$(CH_2)_k$-heteroaryl group is optionally substituted anywhere on said group with one or more R^{12} groups~~, or, with the carbon to which R^1 and R^2 are attached, are connected to form a C_3-C_7 cycloalkyl or a 4-7 membered carbocyclic or heterocycloalkyl comprising from one to three hetero moities selected from O, S, -C(=O)-, and N; and wherein said cycloalkyl or heterocycloalkyl optionally contains one or more double bonds; and wherein said cycloalkyl or heterocycloalkyl is optionally fused to or substituted with a C_6-C_{14} aryl or 5-14 membered heteroaryl group; wherein said C_3-C_7 cycloalkyl or 4-7 membered carbocyclic or heterocycloalkyl formed by R^1 and R^2 can each optionally be substituted by from one to three R^{12} groups, and said optionally fused or substituted aryl or heteroaryl, substituted alkyl, substituted aryl optionally fused aryl or heteroaryl may each optionally independently be substituted with from one to six R^{12} groups in any stereochemical relationship~~;

wherein the R^{12} groups are independently selected from H, R^{13}, R^{16}, -C_1-C_4 alkyl optionally containing one or two unsaturated bonds, halogen, -OR^{13}, -NO_2, -CN, -C_3-C_6 cycloalkyl, aryl, substituted aryl, wherein said aryl or substituted aryl is independently optionally substituted with 1-3 R^{18} groups, -$C(R^4)(C_1$-C_4 alkyl)(C_1-C_4 alkyl) wherein said

alkyl groups may form a C_3-C_7 carbocyclic ring, -$(CH_2)_v$-$NR^{13}R^{14}$, -$NR^{13}C(=O)R^{14}$, -$C(=O)NR^{13}R^{14}$, -$OC(=O)R^{13}$, -$C(=O)OR^{13}$, -$C(=O)R^{13}$, -$NR^{13}C(=O)OR^{14}$, -$NR^{13}C(=O)NR^{14}R^{15}$, -$NR^{13}S(=O)_2R^{14}$, -$NR^{17}S(=O)_2NR^{13}R^{14}$ and -$S(=O)_2R^{13}$;

R^{18} is H, F, Cl, -OH, -C_1-C_4 alkyl, -C≡N, -$NR^{13}C(=O)R^{14}$, -$C(=O)NR^{13}R^{14}$, –O(C_1-C_4)alkyl, -NH(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)(C_1-C_4 alkyl), -$(CH_2)_n$OH, -$(CH_2)_n$-C≡N, -$(CH_2)_n$-$NR^{13}C(=O)R^{14}$, -$(CH_2)_n$-$C(=O)NR^{13}R^{14}$, -$(CH_2)_n$-O(C_1-C_4)alkyl, -$(CH_2)_n$-NH_2, -$(CH_2)_n$-NH(C_1-C_4 alkyl) or -$(CH_2)_n$-N(C_1-C_4 alkyl)(C_1-C_4 alkyl);

R^4 is absent or is H, –C_1-C_4 alkyl which may optionally contain one or two unsaturated bonds, –OH, O-(C_1-C_4)alkyl, (C_1-C_4)-alkyl-OH, $(CH_2)_nNH_2$, -$(CH_2)_n$-NH(C_1-C_4 alkyl), $(CH_2)_n$-N(C_1-C_4)alkyl(C_1-C_4)alkyl, -$(CH_2)_n$-NHC(=O)(C_1-C_4 alkyl), -$(CH_2)_n$-NO_2, -$(CH_2)_n$-C≡N,-$(CH_2)_n$-$C(=O)NH_2$, -$(CH_2)_n$-C(=O)NH(C_1-C_4 alkyl) or -$(CH_2)_n$-C(=O)N(C_1-C_4 alkyl) (C_1-C_4 alkyl), CN, NO_2, -OR^{16};

R^3 and R^5 are independently H, alkyl C_1-C_6, substituted alkyl C_1-C_6, cycloalkyl C_1-C_6 and substituted cycloalkyl C_1-C_6, (C_2-C_4)alkyl-O-(C_1-C_4)alkyl, (C_2-C_4)alkyl-NH(C_1-C_4 alkyl), (C_2-C_4)alkyl-N(C_1-C_4 alkyl)(C_1-C_4 alkyl), (C_1-C_4)alkyl-heterocyclic;

R^6 and R^7 are independently C_1-C_4 alkyl;

each R^{13}, R^{14}, and R^{15} are independently selected from H, -C_1-C_4 alkyl, -(C_2-C_4 alkyl)-O-(C_1-C_4-alkyl), -$(CH_2)_v$-$NR^{16}R^{17}$, or a 4- to 7-membered heterocyclic group; or R^{13} and R^{14} when in –$NR^{13}R^{14}$, may optionally be connected to form a 4 to 6 membered heterocyclic group, which heterocyclic group optionally comprises from 1 to 3 further hetero moieties selected from N, S, O and –C(=O);

R^{16} and R^{17} are independently H, C_1-C_6 alkyl or together may form a 4- to 7-membered heterocyclic group;

k is an integer selected from zero, 1, 2, 3, 4, and 5; and

v is an integer selected from 2, 3, 4, and 5; and

n is an integer selected from zero, 1, 2, 3, 4, and 5;

and pharmaceutically acceptable salts thereof;

with the proviso that;

a) in said  group, when n is 0, R^1, R^2 or R^4 cannot be a heteroatom or contain a heteroatom which is directly linked to the carbon of said  group when said carbon is sp^3 hybridized; and

b) R^{13} and R^{14} cannot be H in a $-NHS(=O)_2R^{14}$ or a $-SO_2R^{13}$ group.

2. (Original) The compound according to claim 1 represented by the chemical structure II:



II

Wherein each of X, R^1, R^2, R^3, R^4, R^5, R^6, R^7 and n is represented as described in claim 1 and the preferred relative stereochemistry between R^6 and R^7 is *trans*.

3. (Original) The compound according to claim 2 wherein R^3 and R^5 are H.

4. (Original) The compound according to claim 2 wherein X is H.

5. (Original) The compound according to claim 2 wherein R^6 and R^7 are each CH_3.

6. (Original) The compound according to claim 2 wherein n is 1, 2 or 3.

7. (Original) The compound according to claim 2 wherein R^4 is OH, CH_2OH, NH_2, $NHCOCH_3$ or CN.

8. (Cancelled).

9. (Original) The compound according to claim 6 wherein n is 1.

10. (Original) The compound according to claim 7 wherein R^4 is OH.

11–19. (Cancelled).

20. (Currently Amended) A pharmaceutical composition comprising an effective amount of a compound according to any of claims 1-7 and 9-10 ~~1-19~~ in combination with a pharmaceutically acceptable carrier, excipient or additive.

21. (Currently Amended) A method of treating in a mammal, in need thereof, a disease state, disorder or condition mediated by an opioid receptor or receptors which

method comprises administering to said mammal an amount of a compound according to any of claims 1-7 and 9-10 ~~1-19~~ effective in modulating an opioid receptor or receptors.

22. (Currently Amended) A method of treating in a mammal, in need thereof, a disease state, disorder or condition selected from the group consisting of irritable bowel syndrome, constipation, nausea, vomiting, pruritic dermatoses, psoriasis; eczema; an insect bite; an eating disorder, depression, anxiety, schizophrenia; drug addiction, an opioid overdose, sexual dysfunction, stroke, head trauma, traumatic brain injury, spinal damage, Parkinson's disease, Alzheimer's disease, age-related cognitive decline and Attention Deficit and Hyperactivity Disorder which method comprises administering to said mammal an amount of a compound according to any of claims 1-7 and 9-10 ~~1-19~~ effective in treating said disease state, disorder or condition.

23. (Currently Amended) A method of treating in a mammal, in need thereof, a disease state, disorder or condition selected from the group consisting of irritable bowel syndrome, drug addiction, depression, anxiety, schizophrenia and eating disorders which method comprises administering to said mammal an amount of a compound according to any of claims 1-7 and 9-10 ~~1-19~~ effective in treating said disease state, disorder or condition.

24. (Currently amended) A method of treating in a mammal, in need thereof, a disease state, disorder or condition selected from the group consisting of allergic dermatitis, contact dermatitis, anorexia, bulimia, obesity, alcohol addiction, amphetamine addiction, cocaine addiction, morphine addiction, opium addiction, heroin addiction, erectile dysfunction and impotence, which method comprises administering to said mammal an effective amount of a compound according to any of claims 1-7 and 9-10 ~~1-19~~ for treating said disease state, disorder or condition.

25. – 27. (Cancelled)

28. (Original) A compound according to claim 1 wherein one or more atoms thereof have an atomic mass or mass number different from the atomic mass or mass number usually found in nature, or a pharmaceutically acceptable salt of such compound.

29. (Cancelled).